ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1671 • ACR Convergence 2022

    Current Cervical Cancer Screening Guidelines Are Unsatisfactory for the Needs of Systemic Lupus Erythematosus Patients

    Zehra Kazmi1, Carlos Lorenzo1, Farwa Kazmi2 and Agustin Escalante3, 1University of Texas Health Sciences Center San Antonio, San antonio, TX, 2Gulf Medical University, Ajman, United Arab Emirates, 3University of Texas Health Science Center at San Antonio, San Antonio, TX

    Background/Purpose: HPV infection is a risk factor for cervical cancer. SLE patients have increased rates of HPV infection, cervical dysplasia and cancer. Present guidelines for…
  • Abstract Number: 1672 • ACR Convergence 2022

    The Impact of Systemic Sclerosis (SSc) on Women’s Health Evaluated with a New SSc-specific Patient-reported Questionnaire

    Maria Grazia Lazzaroni1, Liala Moschetti1, Eleonora Pedretti1, Andrea Lojacono2, Francesca Ramazzotto3, Cristina Zanardini3, Zatti Sonia3, Angela Tincani4, Franco Franceschini1, Paolo Airò5 and Laura Andreoli1, 1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 2Obstetrics and Gynecology, ASST Garda, Desenzano del Garda, Brescia, Brescia, Italy, 3Obstetrics and Gynecology, ASST Spedali Civili and University of Brescia, Brescia, Italy, 4Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy, 5Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy

    Background/Purpose: Systemic Sclerosis (SSc) has a strong female predominance and can significantly impair the everyday quality of life of patients. We aimed at designing a…
  • Abstract Number: 1662 • ACR Convergence 2022

    Nationwide Distribution of Other Connective Tissue Disease (OCTD) and Systemic Sclerosis (SSc) in Areas of Environmental Concern

    Noelle Kosarek1, Megan Romano2, Robert Simms3, Angeline Andrew4, Erika Moen4, Patricia pioli4 and Michael Whitfield5, 1Dartmouth Geisel School of Medicine, Lebanon, NH, 2Dartmouth College, Lebanon, NH, 3Dartmouth Hitchcock Medical Center, Lebanon, NH, 4Geisel School of Medicine at Dartmouth, Lebanon, NH, 5Dartmouth Geisel School of Medicine, Department of Biomedical Data Science, Lebanon, NH

    Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs, vascular abnormalities, and autoantibody formation. The etiology…
  • Abstract Number: 1670 • ACR Convergence 2022

    Phase II Clinical Trial to Assess the Safety and Efficacy of Tocilizumab in Combination with Ipilimumab and Nivolumab for Treatment-naïve Metastatic Melanoma

    Noha Abdel-Wahab1, Emma J. Montazari1, Christine A. Spillson1, Salah-Eddine Bentebibel1, Jean H. Tayar1, Maria Suarez-Almazor2, Suhendan Ekmekcioglu1, Daniel H. Johnson3 and Adi Diab1, 1UT MD Anderson Cancer Center, Houston, TX, 2MD Anderson Cancer Center, Houston, TX, 3Ochsner Health, New Orleans, LA

    Background/Purpose: Immune checkpoint inhibitors (ICIs) led to impressive survival benefits in treatment of cancers. However, immune-related adverse events (irAEs) can cause treatment discontinuation and sometimes…
  • Abstract Number: 1683 • ACR Convergence 2022

    Malondialdehyde-Acetaldehyde (MAA) Modified Matrix Gla Protein (MGP) Increases Citrullination by Human Macrophages

    Spencer Jones1, nozima Aripova1, Michael Duryee1, Austin Ragland1, Bryant England1, Ted Mikuls2 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Malondialdehyde and acetaldehyde, by-products of lipid peroxidation, react with free amino groups on proteins to form a stable post-translational modification (PTM), termed MAA. MAA…
  • Abstract Number: 1677 • ACR Convergence 2022

    Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells

    Brian J. Mog1, Elana R. Shaw1, Michael S. Hwang1, Alexander H. Pearlman1, Sarah R. DiNapoli1, Suman Paul1, Chetan Bettegowda1, Nickolas Papadopoulos1, Sandra B. Gabelli1, Michelle Petri2, Antony Rosen1, Shibin Zhou1, Kenneth W. Kinzler1, Bert Vogelstein1 and Maximilian F. Konig1, 1The Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD

    Background/Purpose: Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the treatment of cancer and can be curative. CD19-targeted CAR-T cells hold promise for the treatment…
  • Abstract Number: 1679 • ACR Convergence 2022

    The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes

    Yukiko Kimura1, Sarah Ringold2, George Tomlinson3, Laura Schanberg4, Anne Dennos5, MaryEllen Riordan6, Vincent Del Gaizo7, Katherine Murphy8, Pamela Weiss9, Brian Feldman10, Mei Sing Ong11 and Marc Natter12, 1Hackensack Meridian Health, New York, NY, 2Janssen, Seattle, WA, 3University of Toronto, Toronto, ON, Canada, 4Duke University Medical Center, Durham, NC, 5Duke University, Durham, NC, 6Hackensack Meridian Health, Hackensack, NJ, 7CARRA, Inc, Washington, DC, 8CARRA, Inc, New Orleans, LA, 9Children's Hospital of Philadelphia, Glen Mills, PA, 10Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 11Harvard Pilgrim Institute, Boston, MA, 12Boston Children's Hospital, Boston, MA

    Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinically inactive disease (CID) in untreated polyarticular JIA…
  • Abstract Number: 1675 • ACR Convergence 2022

    Effectiveness of Intensive Diet and Exercise on Knee Pain Among Communities with Knee Osteoarthritis, Overweight, and Obesity: The WE-CAN Pragmatic Randomized Clinical Trial

    Stephen Messier1, Daniel Beavers2, Kate Queen3, Shannon Mihalko1, Gary Miller1, Elena Losina4, Jeffrey Katz4, Richard Loeser5, Paul DeVita6, David Hunter7, Jovita Newman1, Sara Quandt8, Mary Lyles2, Joanne Jordan9 and Leigh Callahan10, 1Wake Forest University, Winston-Salem, NC, 2Wake Forest University School of Medicine, Winston-Salem, NC, 3Haywood Regional Medical Center, Waynesville, NC, 4Brigham and Women's Hospital, Boston, MA, 5University of North Carolina, Chapel Hill, NC, 6East Carolina University, Greenville, NC, 7University of Sydney, Sydney, Australia, 8Wake Forest School of Medicine, Winston-Salem, NC, 9University of North Carolina School of Medicine, Chapel Hill, NC, 10University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC

    Background/Purpose: Many health systems that treat people with knee osteoarthritis (OA) have no infrastructure in place to implement weight loss and exercise treatments. The policy…
  • Abstract Number: 1686 • ACR Convergence 2022

    Post-translational Modification of Matrix-gla Protein with Malondialdehyde-Acetaldehyde Alters Cellular Responses by Human Fibroblasts

    Austin Ragland1, Michael Duryee1, nozima Aripova1, Spencer Jones1, Ted Mikuls2 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Post-translational modifications with malondialdehyde-acetaldehyde (MAA) alter protein structure and function, inducing pro-inflammatory and pro-fibrotic responses characteristic of rheumatoid arthritis (RA). Matrix-gla protein (MGP) chelates…
  • Abstract Number: 1688 • ACR Convergence 2022

    Biomechanical Phenotype of Circulating Neutrophils Is Altered in ANCA Associated Vasculitis

    Noelle Pisacano1, Stephen P. McAdoo1, Jochen Guck2, Charles D. Pusey1, Edwin R. Chilvers1, Andrew S. Cowburn1, Katharine M. Lodge1 and Maria F. Prendecki1, 1Imperial College London, London, United Kingdom, 2Max Planck Institute, Erlangen, Germany

    Background/Purpose: Real Time-Deformability Cytometry (RT-DC) is a novel technique able to identify morpho-rheological characteristics of individual cells such as size, deformability, and elasticity using only…
  • Abstract Number: 1685 • ACR Convergence 2022

    The Presence of Anti-MAA Antibodies to Extracellular Matrix Proteins in Synovial Fluid and Sera of Patients with Rheumatoid Arthritis

    Alexandra Taylor1, Michael Duryee2, Carlos Hunter2, nozima Aripova2, Ted Mikuls3 and Geoffrey Thiele2, 1Creighton University School of Medicine, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Antibodies to malondialdehyde-acetaldehyde protein adducts (MAA) are increased in both the serum and synovial joint fluid from patients with Rheumatoid Arthritis (RA). These antibodies…
  • Abstract Number: 1687 • ACR Convergence 2022

    A Core Inflammation Program Conserved Across Human and Murine Neutrophils

    Nicolaj hackert1, Felix Radtke1, Tarik Exner1, Carsten Müller-Tidow1, Hanns-Martin Lorenz1, Peter Nigrovic2, Guido Wabnitz1 and Ricardo Grieshaber-Bouyer1, 1Heidelberg University Hospital, Heidelberg, Germany, 2Boston Children's Hospital, Boston, MA

    Background/Purpose: Neutrophils mediate a range of homeostatic and inflammatory processes and display substantial phenotypic and functional heterogeneity. While animal models enable important mechanistic discoveries, differences…
  • Abstract Number: 1178 • ACR Convergence 2022

    Key Features of Human Fibrosing Interstitial Lung Disease Are Captured in a Preclinical Mouse Model upon Repetitive, but Not Single Intratracheal Bleomycin Dosing

    David Lauer1, Janine Schniering2, Matthias Brunner1, Chantal Meier3, Kerstin Klein1, Oliver Distler4 and Britta Maurer1, 1Department of Rheumatology and Immunology, University Hospital Bern, University of Bern, Bern, Switzerland, 2Helmholtz Zentrum München, Institute of Lung Health and Immunity (LHI), Comprehensive Pneumonology Center, Munich, Germany, 3Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland

    Background/Purpose: Repetitive alveolar epithelial injury together with dysregulated tissue repair is crucial for the transition of acute self-limiting to chronic-persisting inflammation and fibrosis in fibrosing…
  • Abstract Number: 1629 • ACR Convergence 2022

    AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases

    Shawn Morales, Jennifer Cross and Robert Huizinga, Aurinia Pharmaceuticals, Inc., Victoria, BC, Canada

    Background/Purpose: AUR200 targets both B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are key mediators in the pathogenesis of B cell-mediated autoimmune…
  • Abstract Number: 1579 • ACR Convergence 2022

    The TICOG Study: Tight Control of Gout – A Randomized, Controlled Trial of Targeted versus Conventional Treatment for Gout Including Ultrasonography

    Sarah Black, Natalie McKee, Jonathan McKnight, Annmarie McShane, Adrian Pendleton, Taggart Alister and Gary Wright, Musgrave Park Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom

    Background/Purpose: Gout is a common inflammatory arthritis triggered by deposition of monosodium urate crystals in joints, bone and soft tissues, with a prevalence of 1-4%…
  • « Previous Page
  • 1
  • …
  • 592
  • 593
  • 594
  • 595
  • 596
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology